Skip to main content
Altuviiio logo

ALTUVIIIO® Patient Experiences 


Beyond the Clinic: A Shared Approach to Treatment Decisions

Watch Dr Janbain and Eli spend the day together as they share his experience of switching to ALTUVIIIO.

Explore more stories of patients who made the switch to ALTUVIIIO

Which patients do you typically see in your practice?

Male adult patients discuss what drove them to make a change

Brad

“I was constantly having bleeds when I was active.”

Chris

"I’ve tried 7 different treatments over my lifetime.”

Daniel

“I was managing my hemophilia, but that was before college.”

Derek

“ALTUVIIIO helped my daughter Brooklynn. I thought it would work for me.”

DJ

“I wanted less time infusing and more time with my son.”

Mickey

“I really wanted fewer infusions.”

Tommy

"As an outdoorsman, my joint health is especially important to me.”

Pediatric and adolescent patients and their caregivers discuss evolving needs

Allison and Emilio

"With his schedule, it’s important for us to be confident in his bleed protection.”

Ashley and Harrison

“My son was still having to get factor while on subcutaneous prophylaxis.”

Nika and Zander

“Since ALTUVIIIO, he hasn’t been constantly infusing.”

 

Jenny and Paxton

“Paxton was experiencing more breakthrough bleeding with his old treatment.” 

Female patients discuss their unique treatment journeys

Brooklynn

“I needed a medicine with bleed protection.”

Chrissy

"My prophylaxis regimen wasn’t working for me.”

Courtney

“Before ALTUVIIIO, I kept having breakthrough bleeding.”

Morgan

"I had a health scare that required surgery, so I sought a factor replacement therapy."

Indication

ALTUVIIIO® is indicated for use in adults and pediatric patients with hemophilia A (congenital factor VIII deficiency) for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding
Limitation of Use

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Contraindications

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

Warnings and Precautions
  • Allergic-type hypersensitivity reactions, including anaphylaxis, have occurred with ALTUVIIIO. Discontinue use of ALTUVIIIO if hypersensitivity reaction occurs and manage symptoms as appropriate.
  • Formation of neutralizing antibodies (inhibitors) to Factor VIII has been reported following administration of ALTUVIIIO. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level.
Adverse Reactions

The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.

Indication

Important Safety Information

© 2026 Sanofi. All rights reserved. All trademarks mentioned are the property of the Sanofi group. MAT-US-2508205-v3.0-08/2026 Last Updated: August 2026